A Phase 2 interventional study of Everolimus and Letrozole in Hormone Receptor Positive Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 52 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing everolimus in Breast Neoplasms — 7 open to participants now, 10 under way, 6 of them phase 3. Everolimus · Breast Neoplasms.
Among the 78 studies testing everolimus in Breast Neoplasms, this one is the 19th largest by enrollment, is one of 11 that started in 2013, is one of 40 in phase 2, and was the 37th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →7 of the 78 studies testing everolimus in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
MedSIR · Sites in Austria, Brazil, Czechia and 6 more countries
Ages 18+
Fudan University · Sites in China
Ages 18–70 · Women only
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 48 · Phase 3 17 · Phase 4 2
First in 2005; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 55 across the 78 interventional studies. Of the 57 that completed or were terminated, 35 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 57th largest by enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2013, is one of 39 in phase 2, and was the 93rd registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing everolimus in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062965Phase 3PfizerA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | 2027-07-22 |
| NCT06382948Phase 3MedSIRElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 78 studies testing everolimus in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the efficacy and safety of first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.
Moreover, the study also aimed to investigate the efficacy and safety of second line treatment with everolumus plus examestane in participants whose disease progressed during everolimus plus letrozole therapy.
This was an open-label, phase II, multicenter, international, single-arm study for postmenopausal women with ER+/HER2- metastatic or locally advanced breast cancer.
This study was comprised of 2 phases:
During the core phase, all enrolled participants received everolimus in combination with letrozole in the first line setting until disease progression or any other reason for which the participant might be discontinued. Only those participants who had disease progression in the first line setting were offered second line treatment (everolimus in combination with exemestane). Participants who discontinued first line treatment due to reasons other than disease progression were not eligible for second line treatment. The participants who were treated in the second line setting continued treatment until disease progression, unacceptable toxicity or withdrawal of consent.
This study included a randomized, open-label sub-study for participants in countries where the alcohol-free 0.5mg/5ml dexamethasone oral solution was commercially available who experienced a stomatitis event: at the first onset of symptoms suggestive of stomatitis, participants were to contact the study site and based on preliminary confirmation of diagnosis, participants were asked to visit the study site within 24 hours. Upon confirmation of stomatitis, participants in countries where the alcohol-free 0.5 mg/5 mL dexamethasone oral solution was commercially available (US sites only) were randomly assigned in a 1:1 ratio to take either 0.5 mg/5 mL dexamethasone mouth rinse or the standard of care used to treat stomatitis at the participant's center.
All participants who experienced stomatitis (regardless of inclusion in the sub-study) were instructed to fill out the Oral Stomatitis Daily Questionnaire (OSDQ) at home every day until the participant recovered. For subsequent episodes of stomatitis, participants were instructed to contact the physician. If part of the randomized set upon telephone confirmation, they were instructed to utilize the same treatment they were assigned to after the first episode and complete the OSDQ booklet.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria might apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received everolimus in combination with letrozole as first-line treatment. Only participants who had disease progression in the first line setting (core phase) were offered second-line treatment (everolimus in combination with exemestane)
Drug: Everolimus · Drug: Letrozole · Drug: Exemestane · Drug: Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study) · Drug: Standard of care to treat stomatitis (Stomatitis sub-study)
Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
Also known as: RAD001
1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
Also known as: Femara
2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
Also known as: Aromasin
Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
First-line Treatment: Progression-free Survival (PFS)
PFS in the first line setting is defined as the time from the date of enrollment to the date of first documented progression based on local radiology review or death due to any cause. If a participant did not progress or was not known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. The median PFS was estimated and presented along with 95% confidence intervals. The primary analysis of PFS for first line was performed 12 months after the last patient's recruitment.
Time frame: From the date of enrollment to the date of first documented progression or deaths, assessed up to approximately 2.8 years
First-line Treatment: Overall Response Rate (ORR)
ORR in first line setting is defined as the percentage of participants while on first-line treatment with best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.0 based on local review. Confidence intervals were calculated based on the Exact Clopper-Pearson method. ORR while on first-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.
Time frame: From the date of enrollment until discontinuation of first-line treatment, assessed up to approximately 3.8 years
First-line Treatment: Clinical Benefit Rate (CBR)
CBR in first line is defined as the percentage of participants while on first-line treatment with best overall response of CR, PR or stable disease (SD) with a duration of 24 weeks or longer, according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. CBR while on first-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease
Time frame: From the date of enrollment until first-line treatment discontinuation, assessed up to approximately 3.8 years
Second-line Treatment: Progression-free Survival (PFS)
PFS in the second line setting is defined as the time interval between the start of the second-line treatment and documented disease progression based on local radiology review or death due to any cause reported during or after second-line treatment period. If a participant did not progress or was not known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. The median PFS was estimated and presented along with 95% confidence intervals. PFS while on second-line treatment was assessed up to 24 months after the last patient's recruitment.
Time frame: From the start of the second-line treatment until the date of first documented progression or death, assessed up to approximately 2.4 years
Second-line Treatment: Overall Response Rate (ORR)
ORR in second line is defined as the percentage of participants receiving second-line study treatment with best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. ORR while on second-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters
Time frame: From the start of the second-line treatment up to approximately 2.4 years
Second-line Treatment: Clinical Benefit Rate (CBR)
CBR in second line is defined as the percentage of participants receiving second-line study treatment with best overall response of CR, PR or stable disease (SD) with a duration of 24 weeks or longer, according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. CBR while on second-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease
Time frame: From the start of the second-line treatment up to approximately 2.4 years
Overall Survival (OS)
OS following first-line treatment with everolimus + letrozole is defined as the time from the date of receiving first line study treatment to date of death due to any cause (including first-line and second-line treatment periods). If a participant was not known to have died, survival was censored at the date of last contact. OS following first-line treatment was assessed up to 24 months after last patient's recruitment.
Time frame: From the date of enrollment to date of death, assessed up to approximately 3.8 years
First-line Treatment: Time to First Stomatitis Episode as Assessed by the Oral Stomatitis Daily Questionnaire (OSDQ)
The time to first occurrence of stomatitis based on OSDQ is defined as time from first-line treatment administration to start date of the stomatitis episode recorded in the OSDQ in the first line. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The first item asked the participants when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. Patient reported outcomes (PROs) were assessed up to 24 months after last patient's recruitment.
Time frame: From first-line treatment administration until first stomatitis episode in the first line, assessed up to approximately 3.8 years
First-line Treatment: Duration of First Stomatitis Based on OSDQ
The duration of the first stomatitis episode was calculated using the start and end date recorded in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis. The first item of the questionnaire asked the participants the date when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. Stop date of the first stomatitis episode is defined as the last date the OSDQ was completed for this episode. Participants were censored if they died before resolution of stomatitis, received a new anticancer therapy, discontinued the study treatment with no resolution of the stomatitis or the stomatitis event was still on-going at the cut-off. PROs were assessed up to 24 months after last patient's recruitment.
Time frame: From start date of first stomatitis episode in first line until its resolution, assessed up to 3.8 years
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Overall Health at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily up to the resolution of the stomatitis episode. The second item asked the participant to rate their overall health from 0 (worst possible) to 10 (perfect health). The overall health OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The third item asked the participant to rate their mouth and throat soreness from 0 (no soreness) to 4 (extreme soreness). The mouth and throat soreness OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness Limiting Swallowing, Drinking, Eating, Talking and Sleeping at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fourth item asked the participant to rate how much their mouth and throat soreness limited them in 1) swallowing, 2) drinking, 3) eating, 4) talking and 5) sleeping. For each activity, mouth and throat soreness scores ranged from 0 (not limited) to 4 (unable to do). Scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fifth item asked the participant to rate their mouth pain severity from 0 (no pain) to 10 (unbearable pain). The mouth pain severity OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment: Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity Affecting Daily Activities at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The sixth item asked the participant to rate their mouth pain severity affecting daily activities score from 0 (no effect on daily activities) to 10 (completely prevented from doing daily activities). The mouth pain severity affecting daily activities OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment (Stomatitis Sub-study): Time to First Stomatitis Episode as Assessed by the OSDQ
The time to first occurrence of stomatitis based on OSDQ is defined as time from first study treatment administration in the first line to start date of the first stomatitis episode recorded in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The first item asked the participants when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
Time frame: From first study treatment administration in the first line until first stomatitis episode, assessed up to approximately 3.8 years
First-line Treatment (Stomatitis Sub-study): Duration of First Stomatitis Based on OSDQ
The duration of the first stomatitis was calculated using the start and end date reported in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis. The first item asked the participants the date when they experienced the first symptoms of stomatitis. Start date of the first stomatitis is defined as the first date ever recorded for this item in the questionnaire. Stop date of the first stomatitis is defined as the last date the OSDQ was completed for this episode. Participants were censored if they died before resolution of stomatitis, received a new anticancer therapy, discontinued the study treatment with no resolution of the stomatitis or the stomatitis was still on-going at the cut-off. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Overall Health at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The second item asked the participant to rate their overall health from 0 (worst possible) to 10 (perfect health). The overall health OSDQ score are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The third item asked the participant to rate their mouth and throat soreness from 0 (no soreness) to 4 (extreme soreness). The mouth and throat soreness OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
Time frame: From start date of stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth and Throat Soreness Limiting Swallowing, Drinking, Eating, Talking and Sleeping at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fourth item asked the participant to rate how much their mouth and throat soreness limited them in 1) swallowing, 2) drinking, 3) eating, 4) talking and 5) sleeping. For each activity, mouth and throat soreness scores ranged from 0 (not limited) to 4 (unable to do). Scores are presented as the shift from Day 1 of first stomatitis stomatitis value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first episode value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fifth item asked the participant to rate their mouth pain severity from 0 (no pain) to 10 (unbearable pain). The mouth pain severity OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
First-line Treatment (Stomatitis Sub-study): Number of Participants With Shift of Response in OSDQ Score on Mouth Pain Severity Affecting Daily Activities at the End of the First Stomatitis Episode
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The sixth item asked the participant to rate their mouth pain severity affecting daily activities score from 0 (no effect on daily activities) to 10 (completely prevented from doing daily activities). The mouth pain severity affecting daily activities OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
Time frame: From start date of first stomatitis episode until its resolution, assessed up to 3.8 years
Number of Participants With Clinical Benfit During Extension Phase
Number of participants with clinical benefit as judged by the investigator during the extension phase. The extension phase for up to 3 years for participants who were continuing to benefit from study treatment following the end of the core study phase (24 months after last patient's recruitment) was added in the amendment 5 (dated 14-Feb-2017). Results are presented by line of treatment
Time frame: From the end of core phase (upon approval of amendment 5) up to approximately 3 years
The study was conducted across 52 centers in 13 countries.
| Milestone | Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment) |
|---|---|
| Started | 202 |
| Dexamethasone randomized set (stomatitis sub-study) | 11 |
| Standard of care randomized set (stomatitis sub-study) | 13 |
| Completed | 29 |
| Not completed | 173 |
| Withdrew: Adverse event | 33 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Death | 2 |
| Withdrew: Disease progression | 120 |
| Withdrew: Physician decision | 7 |
| Milestone | Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment) |
|---|---|
| Started | 53 |
| Completed | 7 |
| Not completed | 46 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Death | 1 |
| Withdrew: Disease progression | 38 |
| Withdrew: Physician decision | 3 |
PFS in the first line setting is defined as the time from the date of enrollment to the date of first documented progression based on local radiology review or death due to any cause. If a participant did not progress or was not known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. The median PFS was estimated and presented along with 95% confidence intervals. The primary analysis of PFS for first line was performed 12 months after the last patient's recruitment.
| Months | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| First-line Treatment: Progression-free Survival (PFS) | NA (18.0 to NA) |
ORR in first line setting is defined as the percentage of participants while on first-line treatment with best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.0 based on local review. Confidence intervals were calculated based on the Exact Clopper-Pearson method. ORR while on first-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.
| Percentage of participants | Everolimus+Letrozole (First Line Treatment) |
|---|---|
| First-line Treatment: Overall Response Rate (ORR) | 45.0 (38.1 to 52.2) |
CBR in first line is defined as the percentage of participants while on first-line treatment with best overall response of CR, PR or stable disease (SD) with a duration of 24 weeks or longer, according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. CBR while on first-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease
| Percentage of participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| First-line Treatment: Clinical Benefit Rate (CBR) | 74.3 (67.7 to 80.1) |
PFS in the second line setting is defined as the time interval between the start of the second-line treatment and documented disease progression based on local radiology review or death due to any cause reported during or after second-line treatment period. If a participant did not progress or was not known to have died at the date of the analysis cut-off or start of another antineoplastic therapy, the PFS date was censored to the date of last adequate tumor assessment prior to cut-off date or start of antineoplastic therapy. The median PFS was estimated and presented along with 95% confidence intervals. PFS while on second-line treatment was assessed up to 24 months after the last patient's recruitment.
| Months | Everolimus+Exemestane (Second Line Treatment) |
|---|---|
| Second-line Treatment: Progression-free Survival (PFS) | 3.7 (1.9 to 7.4) |
ORR in second line is defined as the percentage of participants receiving second-line study treatment with best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. ORR while on second-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters
| Percentage of participants | Everolimus+Exemestane (Second-line Treatment) |
|---|---|
| Second-line Treatment: Overall Response Rate (ORR) | 6.0 (1.3 to 16.5) |
CBR in second line is defined as the percentage of participants receiving second-line study treatment with best overall response of CR, PR or stable disease (SD) with a duration of 24 weeks or longer, according to RECIST version 1.0 based on local review. Confidence intervals (CI) were calculated based on the Exact Clopper-Pearson method. CBR while on second-line treatment was assessed up to 24 months after the last patient's recruitment. CR: disappearance of all target lesions PR: at least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease
| Percentage of participants | Everolimus+Exemestane (Second-line Treatment) |
|---|---|
| Second-line Treatment: Clinical Benefit Rate (CBR) | 28.0 (16.2 to 42.5) |
OS following first-line treatment with everolimus + letrozole is defined as the time from the date of receiving first line study treatment to date of death due to any cause (including first-line and second-line treatment periods). If a participant was not known to have died, survival was censored at the date of last contact. OS following first-line treatment was assessed up to 24 months after last patient's recruitment.
| Months | Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment) |
|---|---|
| Overall Survival (OS) | NA (37.0 to NA) |
The time to first occurrence of stomatitis based on OSDQ is defined as time from first-line treatment administration to start date of the stomatitis episode recorded in the OSDQ in the first line. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The first item asked the participants when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. Patient reported outcomes (PROs) were assessed up to 24 months after last patient's recruitment.
| Weeks | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| First-line Treatment: Time to First Stomatitis Episode as Assessed by the Oral Stomatitis Daily Questionnaire (OSDQ) | 1.7 (1.3 to 2.1) |
The duration of the first stomatitis episode was calculated using the start and end date recorded in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis. The first item of the questionnaire asked the participants the date when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. Stop date of the first stomatitis episode is defined as the last date the OSDQ was completed for this episode. Participants were censored if they died before resolution of stomatitis, received a new anticancer therapy, discontinued the study treatment with no resolution of the stomatitis or the stomatitis event was still on-going at the cut-off. PROs were assessed up to 24 months after last patient's recruitment.
| Weeks | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| First-line Treatment: Duration of First Stomatitis Based on OSDQ | 12.3 (4.1 to 23.1) |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily up to the resolution of the stomatitis episode. The second item asked the participant to rate their overall health from 0 (worst possible) to 10 (perfect health). The overall health OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
| Participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| From 0 (Day 1) to 0 (end of first stomatitis) | 2 |
| From 0 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 0 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 1 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 1 (Day 1) to 2 (end of first stomatitis) | 1 |
| From 2 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 2 (Day 1) to 8 (end of first stomatitis) | 2 |
| From 3 (Day 1) to 0 (end of first stomatitis) | 1 |
| From 3 (Day 1) to 3 (end of first stomatitis) | 3 |
| From 3 (Day 1) to 5 (end of first stomatitis) | 2 |
| From 3 (Day 1) to 10 (end of first stomatitis) | 2 |
| From 4 (Day 1) to 3 (end of first stomatitis) | 2 |
| From 4 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 4 (Day 1) to 7 (end of first stomatitis) | 1 |
| From 4 (Day 1) to 8 (end of first stomatitis) | 2 |
| From 5 (Day 1) to 0 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 3 (end of first stomatitis) | 3 |
| From 5 (Day 1) to 4 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 5 (end of first stomatitis) | 7 |
| From 5 (Day 1) to 6 (end of first stomatitis) | 4 |
| From 5 (Day 1) to 7 (end of first stomatitis) | 3 |
| From 5 (Day 1) to 9 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 10 (end of first stomatitis) | 2 |
| From 6 (Day 1) to 5 (end of first stomatitis) | 2 |
| From 6 (Day 1) to 6 (end of first stomatitis) | 3 |
| From 6 (Day 1) to 7 (end of first stomatitis) | 2 |
| From 6 (Day 1) to 9 (end of first stomatitis) | 2 |
| From 7 (Day 1) to 3 (end of first stomatitis) | 2 |
| From 7 (Day 1) to 4 (end of first stomatitis) | 1 |
| From 7 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 7 (Day 1) to 7 (end of first stomatitis) | 3 |
| From 7 (Day 1) to 9 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 7 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 8 (end of first stomatitis) | 4 |
| From 8 (Day 1) to 9 (end of first stomatitis) | 5 |
| From 8 (Day 1) to 10 (end of first stomatitis) | 2 |
| From 9 (Day 1) to 0 (end of first stomatitis) | 1 |
| From 9 (Day 1) to 4 (end of first stomatitis) | 2 |
| From 9 (Day 1) to 8 (end of first stomatitis) | 1 |
| From 9 (Day 1) to 9 (end of first stomatitis) | 8 |
| From 10 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 10 (Day 1) to 9 (end of first stomatitis) | 1 |
| From missing value (Day 1) to missing value (end of first stomatitis) | 3 |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The third item asked the participant to rate their mouth and throat soreness from 0 (no soreness) to 4 (extreme soreness). The mouth and throat soreness OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
| Participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| From 0 (Day 1) to 0 (end of first stomatitis) | 3 |
| From 1 (Day 1) to 0 (end of first stomatitis) | 22 |
| From 1 (Day 1) to 1 (end of first stomatitis) | 12 |
| From 1 (Day 1) to 2 (end of first stomatitis) | 3 |
| From 2 (Day 1) to 0 (end of first stomatitis) | 13 |
| From 2 (Day 1) to 1 (end of first stomatitis) | 7 |
| From 2 (Day 1) to 2 (end of first stomatitis) | 4 |
| From 2 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 3 (Day 1) to 0 (end of first stomatitis) | 9 |
| From 3 (Day 1) to 1 (end of first stomatitis) | 4 |
| From 3 (Day 1) to 2 (end of first stomatitis) | 5 |
| From 3 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 3 (Day 1) to 4 (end of first stomatitis) | 1 |
| From 4 (Day 1) to 1 (end of first stomatitis) | 2 |
| From 4 (Day 1) to 2 (end of first stomatitis) | 1 |
| From missing value (Day 1) to missing value (end of first stomatitis) | 4 |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fourth item asked the participant to rate how much their mouth and throat soreness limited them in 1) swallowing, 2) drinking, 3) eating, 4) talking and 5) sleeping. For each activity, mouth and throat soreness scores ranged from 0 (not limited) to 4 (unable to do). Scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
| Participants | Everolimus+Letrozole (First Line Treatment) |
|---|---|
| Swallowing: From 0 (Day 1) to 0 (end of first stomatitis) | 40 |
| Swallowing: From 0 (Day 1) to 1 (end of first stomatitis) | 3 |
| Swallowing: From 0 (Day 1) to 2 (end of first stomatitis) | 1 |
| Swallowing: From 1 (Day 1) to 0 (end of first stomatitis) | 7 |
| Swallowing: From 1 (Day 1) to 1 (end of first stomatitis) | 6 |
| Swallowing: From 1 (Day 1) to 2 (end of first stomatitis) | 3 |
| Swallowing: From 1 (Day 1) to 3 (end of first stomatitis) | 1 |
| Swallowing: From 2 (Day 1) to 0 (end of first stomatitis) | 6 |
| Swallowing: From 2 (Day 1) to 1 (end of first stomatitis) | 4 |
| Swallowing: From 2 (Day 1) to 2 (end of first stomatitis) | 2 |
| Swallowing: From 3 (Day 1) to 0 (end of first stomatitis) | 8 |
| Swallowing: From 3 (Day 1) to 1 (end of first stomatitis) | 2 |
| Swallowing: From 3 (Day 1) to 3 (end of first stomatitis) | 2 |
| Swallowing: From missing value (Day 1) to missing value (end of first stomatitis) | 7 |
| Drinking: From 0 (Day 1) to 0 (end of first stomatitis) | 48 |
| Drinking: From 0 (Day 1) to 1 (end of first stomatitis) | 4 |
| Drinking: From 0 (Day 1) to 2 (end of first stomatitis) | 1 |
| Drinking: From 1 (Day 1) to 0 (end of first stomatitis) | 10 |
| Drinking: From 1 (Day 1) to 1 (end of first stomatitis) | 5 |
| Drinking: From 1 (Day 1) to 2 (end of first stomatitis) | 1 |
| Drinking: From 2 (Day 1) to 0 (end of first stomatitis) | 4 |
| Drinking: From 2 (Day 1) to 1 (end of first stomatitis) | 3 |
| Drinking: From 2 (Day 1) to 2 (end of first stomatitis) | 3 |
| Drinking: From 2 (Day 1) to 3 (end of first stomatitis) | 2 |
| Drinking: From 3 (Day 1) to 0 (end of first stomatitis) | 6 |
| Drinking: From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| Drinking: From 3 (Day 1) to 3 (end of first stomatitis) | 1 |
| Drinking: From missing value (Day 1) to missing value (end of first stomatitis) | 9 |
| Eating: From 0 (Day 1) to 0 (end of first stomatitis) | 17 |
| Eating: From 0 (Day 1) to 1 (end of first stomatitis) | 2 |
| Eating: From 0 (Day 1) to 2 (end of first stomatitis) | 1 |
| Eating: From 1 (Day 1) to 0 (end of first stomatitis) | 14 |
| Eating: From 1 (Day 1) to 1 (end of first stomatitis) | 11 |
| Eating: From 1 (Day 1) to 2 (end of first stomatitis) | 2 |
| Eating: From 2 (Day 1) to 0 (end of first stomatitis) | 8 |
| Eating: From 2 (Day 1) to 1 (end of first stomatitis) | 3 |
| Eating: From 2 (Day 1) to 2 (end of first stomatitis) | 4 |
| Eating: From 2 (Day 1) to 3 (end of first stomatitis) | 2 |
| Eating: From 3 (Day 1) to 0 (end of first stomatitis) | 7 |
| Eating: From 3 (Day 1) to 1 (end of first stomatitis) | 6 |
| Eating: From 3 (Day 1) to 2 (end of first stomatitis) | 3 |
| Eating: From 3 (Day 1) to 3 (end of first stomatitis) | 4 |
| Eating: From 4 (Day 1) to 1 (end of first stomatitis) | 1 |
| Eating: From missing value (Day 1) to missing value (end of first stomatitis) | 7 |
| Talking: From 0 (Day 1) to 0 (end of first stomatitis) | 45 |
| Talking: From 0 (Day 1) to 1 (end of first stomatitis) | 5 |
| Talking: From 1 (Day 1) to 0 (end of first stomatitis) | 12 |
| Talking: From 1 (Day 1) to 1 (end of first stomatitis) | 2 |
| Talking: From 2 (Day 1) to 0 (end of first stomatitis) | 5 |
| Talking: From 2 (Day 1) to 1 (end of first stomatitis) | 2 |
| Talking: From 2 (Day 1) to 2 (end of first stomatitis) | 3 |
| Talking: From 2 (Day 1) to 3 (end of first stomatitis) | 1 |
| Talking: From 3 (Day 1) to 0 (end of first stomatitis) | 4 |
| Talking: From 3 (Day 1) to 2 (end of first stomatitis) | 1 |
| Talking: From 3 (Day 1) to 3 (end of first stomatitis) | 3 |
| Talking: From missing value (Day 1) to missing value (end of first stomatitis) | 9 |
| Sleeping: From 0 (Day 1) to 0 (end of first stomatitis) | 48 |
| Sleeping: From 0 (Day 1) to 1 (end of first stomatitis) | 4 |
| Sleeping: From 0 (Day 1) to 2 (end of first stomatitis) | 1 |
| Sleeping: From 1 (Day 1) to 0 (end of first stomatitis) | 8 |
| Sleeping: From 1 (Day 1) to 1 (end of first stomatitis) | 2 |
| Sleeping: From 1 (Day 1) to 2 (end of first stomatitis) | 2 |
| Sleeping: From 2 (Day 1) to 0 (end of first stomatitis) | 4 |
| Sleeping: From 2 (Day 1) to 1 (end of first stomatitis) | 3 |
| Sleeping: From 2 (Day 1) to 2 (end of first stomatitis) | 6 |
| Sleeping: From 3 (Day 1) to 0 (end of first stomatitis) | 1 |
| Sleeping: From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| Sleeping: From 3 (Day 1) to 2 (end of first stomatitis) | 1 |
| Sleeping: From missing value (Day 1) to missing value (end of first stomatitis) | 11 |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fifth item asked the participant to rate their mouth pain severity from 0 (no pain) to 10 (unbearable pain). The mouth pain severity OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
| Participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| From 0 (Day 1) to 0 (end of first stomatitis) | 5 |
| From 1 (Day 1) to 0 (end of first stomatitis) | 10 |
| From 1 (Day 1) to 1 (end of first stomatitis) | 6 |
| From 1 (Day 1) to 2 (end of first stomatitis) | 1 |
| From 1 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 1 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 2 (Day 1) to 0 (end of first stomatitis) | 6 |
| From 2 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 3 (Day 1) to 0 (end of first stomatitis) | 7 |
| From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 3 (Day 1) to 2 (end of first stomatitis) | 2 |
| From 3 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 3 (Day 1) to 4 (end of first stomatitis) | 2 |
| From 4 (Day 1) to 0 (end of first stomatitis) | 4 |
| From 4 (Day 1) to 1 (end of first stomatitis) | 2 |
| From 4 (Day 1) to 4 (end of first stomatitis) | 1 |
| From 4 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 0 (end of first stomatitis) | 3 |
| From 5 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 2 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 4 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 6 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 7 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 10 (end of first stomatitis) | 1 |
| From 6 (Day 1) to 0 (end of first stomatitis) | 2 |
| From 6 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 6 (Day 1) to 2 (end of first stomatitis) | 1 |
| From 6 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 6 (Day 1) to 6 (end of first stomatitis) | 1 |
| From 6 (Day 1) to 8 (end of first stomatitis) | 1 |
| From 7 (Day 1) to 0 (end of first stomatitis) | 2 |
| From 7 (Day 1) to 1 (end of first stomatitis) | 2 |
| From 7 (Day 1) to 2 (end of first stomatitis) | 1 |
| From 7 (Day 1) to 7 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 0 (end of first stomatitis) | 3 |
| From 8 (Day 1) to 2 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 4 (end of first stomatitis) | 2 |
| From 8 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 6 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 9 (end of first stomatitis) | 1 |
| From 9 (Day 1) to 0 (end of first stomatitis) | 2 |
| From 9 (Day 1) to 9 (end of first stomatitis) | 1 |
| From missing value (Day 1) to missing value (end of first stomatitis) | 4 |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The sixth item asked the participant to rate their mouth pain severity affecting daily activities score from 0 (no effect on daily activities) to 10 (completely prevented from doing daily activities). The mouth pain severity affecting daily activities OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment.
| Participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| From 0 (Day 1) to 0 (end of first stomatitis) | 33 |
| From 0 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 0 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 1 (Day 1) to 0 (end of first stomatitis) | 7 |
| From 1 (Day 1) to 1 (end of first stomatitis) | 4 |
| From 1 (Day 1) to 4 (end of first stomatitis) | 2 |
| From 2 (Day 1) to 0 (end of first stomatitis) | 6 |
| From 2 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 2 (Day 1) to 2 (end of first stomatitis) | 3 |
| From 2 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 2 (Day 1) to 4 (end of first stomatitis) | 1 |
| From 3 (Day 1) to 0 (end of first stomatitis) | 3 |
| From 3 (Day 1) to 1 (end of first stomatitis) | 3 |
| From 3 (Day 1) to 2 (end of first stomatitis) | 1 |
| From 3 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 3 (Day 1) to 4 (end of first stomatitis) | 1 |
| From 4 (Day 1) to 0 (end of first stomatitis) | 2 |
| From 5 (Day 1) to 0 (end of first stomatitis) | 2 |
| From 5 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 2 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 3 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 5 (Day 1) to 6 (end of first stomatitis) | 1 |
| From 6 (Day 1) to 1 (end of first stomatitis) | 1 |
| From 6 (Day 1) to 5 (end of first stomatitis) | 1 |
| From 6 (Day 1) to 8 (end of first stomatitis) | 1 |
| From 7 (Day 1) to 0 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 0 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 8 (end of first stomatitis) | 1 |
| From 8 (Day 1) to 10 (end of first stomatitis) | 1 |
| From 9 (Day 1) to 0 (end of first stomatitis) | 1 |
| From 9 (Day 1) to 8 (end of first stomatitis) | 1 |
| From 10 (Day 1) to 10 (end of first stomatitis) | 1 |
| From missing value (Day 1) to missing value (end of first stomatitis) | 4 |
The time to first occurrence of stomatitis based on OSDQ is defined as time from first study treatment administration in the first line to start date of the first stomatitis episode recorded in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The first item asked the participants when they experienced the first symptoms of stomatitis. Start date of the first occurrence of stomatitis is defined as the first date ever recorded for this item in the questionnaire. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
| Weeks | Everolimus+ Letrozole (First-line Treatment) |
|---|---|
| Dexamethasone | 1.4 (0.9 to 1.9) |
| Standard of care | 2.3 (0.7 to 5.4) |
The duration of the first stomatitis was calculated using the start and end date reported in the OSDQ. The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis. The first item asked the participants the date when they experienced the first symptoms of stomatitis. Start date of the first stomatitis is defined as the first date ever recorded for this item in the questionnaire. Stop date of the first stomatitis is defined as the last date the OSDQ was completed for this episode. Participants were censored if they died before resolution of stomatitis, received a new anticancer therapy, discontinued the study treatment with no resolution of the stomatitis or the stomatitis was still on-going at the cut-off. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
| Weeks | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| Dexamethasone | NA (NA to NA) |
| Standard of Care | 13.7 (1.4 to 13.7) |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The second item asked the participant to rate their overall health from 0 (worst possible) to 10 (perfect health). The overall health OSDQ score are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
| Participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| Dexamethasone: From 2 (Day 1) to 5 (end of first stomatitis) | 1 |
| Dexamethasone: From 4 (Day 1) to 3 (end of first stomatitis) | 1 |
| Dexamethasone: From 5 (Day 1) to 5 (end of first stomatitis) | 1 |
| Dexamethasone: From 5 (Day 1) to 6 (end of first stomatitis) | 1 |
| Dexamethasone: From 5 (Day 1) to 7 (end of first stomatitis) | 1 |
| Dexamethasone: From 6 (Day 1) to 5 (end of first stomatitis) | 1 |
| Dexamethasone: From 6 (Day 1) to 7 (end of first stomatitis) | 1 |
| Dexamethasone: From 7 (Day 1) to 3 (end of first stomatitis) | 1 |
| Dexamethasone: From 8 (Day 1) to 8 (end of first stomatitis) | 1 |
| Dexamethasone: From 8 (Day 1) to 9 (end of first stomatitis) | 1 |
| Dexamethasone: From 9 (Day 1) to 9 (end of first stomatitis) | 1 |
| SoC: From 0 (Day 1) to 5 (end of first stomatitis) | 1 |
| SoC: From 4 (Day 1) to 3 (end of first stomatitis) | 1 |
| SoC: From 4 (Day 1) to 8 (end of first stomatitis) | 1 |
| SoC: From 5 (Day 1) to 5 (end of first stomatitis) | 1 |
| SoC: From 6 (Day 1) to 7 (end of first stomatitis) | 1 |
| SoC: From 7 (Day 1) to 3 (end of first stomatitis) | 1 |
| SoC: From 8 (Day 1) to 9 (end of first stomatitis) | 1 |
| SoC: From 8 (Day 1) to 10 (end of first stomatitis) | 1 |
| SoC: From 9 (Day 1) to 4 (end of first stomatitis) | 1 |
| SoC: From 9 (Day 1) to 9 (end of first stomatitis) | 2 |
| SoC: From missing value (Day 1) to missing value (end of first stomatitis) | 2 |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The third item asked the participant to rate their mouth and throat soreness from 0 (no soreness) to 4 (extreme soreness). The mouth and throat soreness OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
| Participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| Dexamethasone: From 0 (Day 1) to 0 (end of first stomatitis) | 1 |
| Dexamethasone: From 1 (Day 1) to 0 (end of first stomatitis) | 3 |
| Dexamethasone: From 1 (Day 1) to 1 (end of first stomatitis) | 2 |
| Dexamethasone: From 2 (Day 1) to 0 (end of first stomatitis) | 1 |
| Dexamethasone: From 2 (Day 1) to 1 (end of first stomatitis) | 3 |
| Dexamethasone: From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| SoC: From 1 (Day 1) to 0 (end of first stomatitis) | 1 |
| SoC: From 1 (Day 1) to 1 (end of first stomatitis) | 1 |
| SoC: From 2 (Day 1) to 1 (end of first stomatitis) | 1 |
| SoC: From 3 (Day 1) to 0 (end of first stomatitis) | 2 |
| SoC: From 3 (Day 1) to 1 (end of first stomatitis | 1 |
| SoC: From 3 (Day 1) to 2 (end of first stomatitis | 3 |
| SoC: From 4 (Day 1) to 1 (end of first stomatitis | 1 |
| SoC: From 4 (Day 1) to 2 (end of first stomatitis | 1 |
| SoC: From missing value (Day 1) to missing value (end of first stomatitis) | 2 |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fourth item asked the participant to rate how much their mouth and throat soreness limited them in 1) swallowing, 2) drinking, 3) eating, 4) talking and 5) sleeping. For each activity, mouth and throat soreness scores ranged from 0 (not limited) to 4 (unable to do). Scores are presented as the shift from Day 1 of first stomatitis stomatitis value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first episode value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
| Participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| Swallowing (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis) | 6 |
| Swallowing (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis) | 2 |
| Swallowing (dexamethasone): From 1 (Day 1) to 1 (end of first stomatitis) | 1 |
| Swallowing (dexamethasone): From 2 (Day 1) to 0 (end of first stomatitis) | 1 |
| Swallowing (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis) | 1 |
| Swallowing (SoC): From 0 (Day 1) to 0 (end of first stomatitis) | 5 |
| Swallowing (SoC): From 1 (Day 1) to 2 (end of first stomatitis) | 1 |
| Swallowing (SoC): From 2 (Day 1) to 0 (end of first stomatitis) | 1 |
| Swallowing (SoC): From 2 (Day 1) to 1 (end of first stomatitis) | 2 |
| Swallowing (SoC): From 3 (Day 1) to 0 (end of first stomatitis) | 1 |
| Swallowing (SoC): From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| Swallowing (SoC): From missing value (Day 1) to missing value (end of first stomatitis) | 2 |
| Drinking (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis) | 6 |
| Drinking (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis) | 2 |
| Drinking (dexamethasone): From 1 (Day 1) to 1 (end of first stomatitis) | 1 |
| Drinking (dexamethasone): From 2 (Day 1) to 0 (end of first stomatitis) | 1 |
| Drinking (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis) | 1 |
| Drinking (SoC): From 0 (Day 1) to 0 (end of first stomatitis) | 3 |
| Drinking (SoC): From 0 (Day 1) to 1 (end of first stomatitis) | 2 |
| Drinking (SoC): From 2 (Day 1) to 0 (end of first stomatitis) | 3 |
| Drinking (SoC): From 2 (Day 1) to 1 (end of first stomatitis) | 1 |
| Drinking (SoC): From 3 (Day 1) to 0 (end of first stomatitis) | 1 |
| Drinking (SoC): From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| Drinking (SoC): From missing value (Day 1) to missing value (end of first stomatitis) | 2 |
| Eating (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis) | 3 |
| Eating (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis) | 1 |
| Eating (dexamethasone): From 1 (Day 1) to 1 (end of first stomatitis) | 2 |
| Eating (dexamethasone): From 2 (Day 1) to 0 (end of first stomatitis) | 1 |
| Eating (dexamethasone): From 2 (Day 1) to 1 (end of first stomatitis) | 2 |
| Eating (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis) | 1 |
| Eating (dexamethasone): From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| Eating (SoC): From 1 (Day 1) to 0 (end of first stomatitis) | 2 |
| Eating (SoC): From 1 (Day 1) to 1 (end of first stomatitis) | 1 |
| Eating (SoC): From 2 (Day 1) to 0 (end of first stomatitis) | 1 |
| Eating (SoC): From 3 (Day 1) to 0 (end of first stomatitis) | 1 |
| Eating (SoC): From 3 (Day 1) to 1 (end of first stomatitis) | 2 |
| Eating (SoC): From 3 (Day 1) to 2 (end of first stomatitis) | 3 |
| Eating (SoC): From 4 (Day 1) to 1 (end of first stomatitis) | 1 |
| Eating (SoC): From missing value (Day 1) to missing value (end of first stomatitis) | 2 |
| Talking (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis) | 6 |
| Talking (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis) | 1 |
| Talking (dexamethasone): From 2 (Day 1) to 0 (end of first stomatitis) | 2 |
| Talking (dexamethasone): From 2 (Day 1) to 1 (end of first stomatitis) | 1 |
| Talking (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis) | 1 |
| Talking (SoC): From 0 (Day 1) to 0 (end of first stomatitis) | 5 |
| Talking (SoC): From 0 (Day 1) to 1 (end of first stomatitis) | 1 |
| Talking (SoC): From 1 (Day 1) to 0 (end of first stomatitis) | 1 |
| Talking (SoC): From 2 (Day 1) to 0 (end of first stomatitis) | 1 |
| Talking (SoC): From 2 (Day 1) to 1 (end of first stomatitis) | 1 |
| Talking (SoC): From 3 (Day 1) to 0 (end of first stomatitis) | 1 |
| Talking (SoC): From 3 (Day 1) to 2 (end of first stomatitis) | 1 |
| Talking (SoC): From missing value (Day 1) to missing value (end of first stomatitis) | 2 |
| Sleeping (dexamethasone): From 0 (Day 1) to 0 (end of first stomatitis) | 7 |
| Sleeping (dexamethasone): From 1 (Day 1) to 0 (end of first stomatitis) | 1 |
| Sleeping (dexamethasone): From 2 (Day 1) to 0 (end of stomatitis) | 1 |
| Sleeping (dexamethasone): From 2 (Day 1) to 1 (end of first stomatitis) | 1 |
| Sleeping (dexamethasone): From 2 (Day 1) to 2 (end of first stomatitis) | 1 |
| Sleeping (SoC): From 0 (Day 1) to 0 (end of first stomatitis) | 5 |
| Sleeping (SoC): From 0 (Day 1) to 2 (end of first stomatitis) | 1 |
| Sleeping (SoC): From 1 (Day 1) to 1 (end of first stomatitis) | 1 |
| Sleeping (SoC): From 2 (Day 1) to 0 (end of first stomatitis) | 2 |
| Sleeping (SoC): From 3 (Day 1) to 0 (end of first stomatitis) | 1 |
| Sleeping (SoC): From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| Sleeping (SoC): From missing value (Day 1) to missing value (end of first stomatitis) | 2 |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The fifth item asked the participant to rate their mouth pain severity from 0 (no pain) to 10 (unbearable pain). The mouth pain severity OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
| Participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| Dexamethasone: From 0 (Day 1) to 0 (end of first stomatitis) | 1 |
| Dexamethasone: From 1 (Day 1) to 2 (end of first stomatitis) | 1 |
| Dexamethasone: From 2 (Day 1) to 0 (end of first stomatitis) | 2 |
| Dexamethasone: From 3 (Day 1) to 0 (end of first stomatitis) | 2 |
| Dexamethasone: From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| Dexamethasone: From 3 (Day 1) to 2 (end of first stomatitis) | 1 |
| Dexamethasone: From 5 (Day 1) to 2 (end of first stomatitis) | 1 |
| Dexamethasone: From 5 (Day 1) to 3 (end of first stomatitis) | 1 |
| Dexamethasone: From 7 (Day 1) to 1 (end of first stomatitis) | 1 |
| SoC: From 1 (Day 1) to 0 (end of first stomatitis) | 1 |
| SoC: From 1 (Day 1) to 1 (end of first stomatitis) | 1 |
| SoC: From 4 (Day 1) to 1 (end of first stomatitis) | 2 |
| SoC: From 5 (Day 1) to 5 (end of first stomatitis) | 1 |
| SoC: From 7 (Day 1) to 0 (end of first stomatitis) | 1 |
| SoC: From 8 (Day 1) to 2 (end of first stomatitis) | 1 |
| SoC: From 8 (Day 1) to 4 (end of first stomatitis) | 2 |
| SoC: From 8 (Day 1) to 6 (end of first stomatitis) | 1 |
| SoC: From 9 (Day 1) to 0 (end of first stomatitis) | 1 |
| SoC: From missing value (Day 1) to missing value (end of first stomatitis) | 2 |
The OSDQ is a patient self-administered 6-item questionnaire with a 24-hour recall period. Participants completed the questionnaire daily until the resolution of the stomatitis episode. The sixth item asked the participant to rate their mouth pain severity affecting daily activities score from 0 (no effect on daily activities) to 10 (completely prevented from doing daily activities). The mouth pain severity affecting daily activities OSDQ scores are presented as the shift from Day 1 of first stomatitis episode value to the value at the end of the first episode of stomatitis. Day 1 is defined as the first OSDQ questionnaire recorded. End of first stomatitis value is defined as the last OSDQ questionnaire of the first episode of stomatitis. PROs were assessed up to 24 months after last patient's recruitment. Only participants who were randomized in the stomatitis sub-study were included in this analysis.
| Participants | Everolimus+Letrozole (First-line Treatment) |
|---|---|
| Dexamethasone: From 0 (Day 1) to 0 (end of first stomatitis) | 5 |
| Dexamethasone: From 1 (Day 1) to 0 (end of first stomatitis) | 1 |
| Dexamethasone: From 2 (Day 1) to 0 (end of first stomatitis) | 2 |
| Dexamethasone: From 3 (Day 1) to 2 (end of first stomatitis) | 1 |
| Dexamethasone: From 5 (Day 1) to 3 (end of first stomatitis) | 1 |
| Dexamethasone: From 6 (Day 1) to 1 (end of first stomatitis) | 1 |
| SoC: From 0 (Day 1) to 0 (end of first stomatitis) | 4 |
| SoC: From 1 (Day 1) to 4 (end of first stomatitis) | 1 |
| SoC: From 2 (Day 1) to 2 (end of first stomatitis) | 1 |
| SoC: From 3 (Day 1) to 0 (end of first stomatitis) | 1 |
| SoC: From 3 (Day 1) to 1 (end of first stomatitis) | 1 |
| SoC: From 5 (Day 1) to 2 (end of first stomatitis) | 1 |
| SoC: From 5 (Day 1) to 5 (end of first stomatitis) | 1 |
| SoC: From 9 (Day 1) to 0 (end of first stomatitis) | 1 |
| SoC: From missing value (Day 1) to missing value (end of first stomatitis) | 2 |
Number of participants with clinical benefit as judged by the investigator during the extension phase. The extension phase for up to 3 years for participants who were continuing to benefit from study treatment following the end of the core study phase (24 months after last patient's recruitment) was added in the amendment 5 (dated 14-Feb-2017). Results are presented by line of treatment
| Participants | Everolimus+Letrozole (First-line Treatment) | Everolimus+Exemestane (Second-line Treatment) |
|---|---|---|
| Extension Week 1 | 34 | 6 |
| Extension Week 12 | 30 | 5 |
| Extension Week 24 | 28 | 4 |
| Extension Week 36 | 23 | 3 |
| Extension Week 48 | 20 | 3 |
| Extension Week 60 | 18 | 3 |
| Extension Week 72 | 16 | 3 |
| Extension Week 84 | 13 | 3 |
| Extension Week 96 | 12 | 3 |
| Extension Week 108 | 12 | 3 |
| Extension Week 120 | 11 | 2 |
| Extension Week 132 | 10 | 1 |
| Extension Week 144 | 8 | 1 |
| Extension End of treatment | 11 | 1 |
On-treatment deaths in first line were collected from first dose of first-line treatment until the date of last administration of the first-line study treatment plus 28 days for participants not entering second-line or the minimum between the date of last administration of the first-line study treatment plus 28 days and the date of first administration of second-line study treatment minus one day for participants entering second line, up to 7.3 years. On-treatment deaths in second line were collected from first dose of second-line treatment to 28 days after the last administration of second-line treatment, up to 5.4 years. Post-treatment survival follow-up deaths were collected from day 29 after last dose of study treatment to end of study, up to 7.3 years. All deaths refer to the sum of on-treatment deaths and post-treatment deaths.
| Participants | Everolimus + Letrozole/Exemestane (First-line and Second-line Treatment) |
|---|---|
| On -treatment deaths in first line | 11 |
| On-treatment deaths in second line | 2 |
| Post-treatment survival follow-up deaths | 49 |
| All deaths | 62 |
Collected over First-line on-treatment: from the first first-line dose to 28 days post first-line treatment (or 1 day before second-line dose, whichever was earlier, for participants receiving second-line), up to 7.3 years. Second-line on-treatment: from first second-line dose to 28 days post second-line treatment, up to 5.4 years. Post-treatment deaths: from day 29 after final dose to end of study, up to 7.3 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus+Letrozole (First-line on Treatment) | 11/202 (5.4%) | 72/202 (35.6%) | 202/202 (100%) |
| Everolimus+Exemestane (Second-line On-treatment) | 2/53 (3.8%) | 8/53 (15.1%) | 43/53 (81.1%) |
| Everolimus+Letrozole/Exemestane (Post-treatment Survival Follow-up) | 49/125 (39.2%) | — | — |
| Event | Everolimus+Letrozole (First-line on Treatment) | Everolimus+Exemestane (Second-line On-treatment) | Everolimus+Letrozole/Exemestane (Post-treatment Survival Follow-up) |
|---|---|---|---|
| PneumoniaInfections and infestations | 9/202 | 1/53 | — |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/202 | 1/53 | — |
| AnaemiaBlood and lymphatic system disorders | 5/202 | 0/53 | — |
| NauseaGastrointestinal disorders | 5/202 | 0/53 | — |
| Bone painMusculoskeletal and connective tissue disorders | 5/202 | 0/53 | — |
| Atrial fibrillationCardiac disorders | 4/202 | 0/53 | — |
| VomitingGastrointestinal disorders | 4/202 | 0/53 | — |
| CellulitisInfections and infestations | 4/202 | 0/53 | — |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/202 | 1/53 | — |
| Abdominal painGastrointestinal disorders | 1/202 | 1/53 | — |
| Event | Everolimus+Letrozole (First-line on Treatment) | Everolimus+Exemestane (Second-line On-treatment) | Everolimus+Letrozole/Exemestane (Post-treatment Survival Follow-up) |
|---|---|---|---|
| StomatitisGastrointestinal disorders | 139/202 | 10/53 | — |
| Weight decreasedInvestigations | 91/202 | 15/53 | — |
| DiarrhoeaGastrointestinal disorders | 81/202 | 2/53 | — |
| NauseaGastrointestinal disorders | 73/202 | 4/53 | — |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 72/202 | 5/53 | — |
| AnaemiaBlood and lymphatic system disorders | 71/202 | 11/53 | — |
| FatigueGeneral disorders | 70/202 | 5/53 | — |
| CoughRespiratory, thoracic and mediastinal disorders | 70/202 | 7/53 | — |
| Decreased appetiteMetabolism and nutrition disorders | 64/202 | 5/53 | — |
| Oedema peripheralGeneral disorders | 63/202 | 6/53 | — |
| Age, Continuous(Years) | Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment) |
|---|---|
| Mean | 63.5 ± 8.75 |
| Sex: Female, Male(Participants) | Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment) |
|---|---|
| Female | 202 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Everolimus+Letrozole/Exemestane (First-line Treatment and Second-line Treatment) |
|---|---|
| Caucasian | 146 |
| Black | 7 |
| Asian | 44 |
| Pacific islander | 1 |
| Other | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2013 to primary completion in Dec 2015, 33 months.
Results were first posted in Feb 2022, 6 years 1 month after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 33 months is close to that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Everolimus · Letrozole